Peter M Andersen
Overview
Explore the profile of Peter M Andersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
9800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Mehta P, Iacoangeli A, Opie-Martin S, van Vugt J, Al Khleifat A, Bredin A, et al.
Brain
. 2022 Sep;
145(12):4440-4447.
PMID: 36162820
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative syndrome. In up to 20% of cases, a family history is observed. Although Mendelian disease gene variants are found in apparently sporadic...
32.
Schrader T, Carmichael R, Islinger M, Costello J, Hacker C, Bonekamp N, et al.
J Cell Sci
. 2022 Jun;
135(13).
PMID: 35678336
Peroxisome membrane dynamics and division are essential to adapt the peroxisomal compartment to cellular needs. The peroxisomal membrane protein PEX11β (also known as PEX11B) and the tail-anchored adaptor proteins FIS1...
33.
Benatar M, Granit V, Andersen P, Grignon A, McHutchison C, Cosentino S, et al.
Brain
. 2022 May;
145(10):3500-3508.
PMID: 35594156
Amyotrophic lateral sclerosis, when viewed as a biological entity rather than a clinical syndrome, probably evolves along a continuum, with the initial clinically silent phase eventually evolving into clinically manifest...
34.
Benatar M, Wuu J, Andersen P, Bucelli R, Andrews J, Otto M, et al.
Neurotherapeutics
. 2022 May;
19(4):1248-1258.
PMID: 35585374
Despite extensive research, amyotrophic lateral sclerosis (ALS) remains a progressive and invariably fatal neurodegenerative disease. Limited knowledge of the underlying causes of ALS has made it difficult to target upstream...
35.
Hoyer H, Hilmarsen H, Sunder-Plassmann R, Braathen G, Andersen P, Beetz C, et al.
J Med Genet
. 2022 Mar;
59(10):1024-1026.
PMID: 35318247
No abstract available.
36.
Masrori P, Ospitalieri S, Forsberg K, Moens T, Poesen K, Race V, et al.
Eur J Neurol
. 2022 Mar;
29(4):1279-1283.
PMID: 35253968
Background And Purpose: With the advent of gene therapies for amyotrophic lateral sclerosis (ALS), the importance of gene testing in ALS is increasing. This will likely lead to the identification...
37.
Hop P, Zwamborn R, Hannon E, Shireby G, Nabais M, Walker E, et al.
Sci Transl Med
. 2022 Feb;
14(633):eabj0264.
PMID: 35196023
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with an estimated heritability between 40 and 50%. DNA methylation patterns can serve as proxies of (past) exposures and disease progression,...
38.
Kliest T, van Eijk R, Al-Chalabi A, Albanese A, Andersen P, Amador M, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2022 Feb;
23(7-8):481-488.
PMID: 35172656
Pediatric investigation plans (PIPs) describe how adult drugs can be studied in children. In 2015, PIPs for Amyotrophic Lateral Sclerosis (ALS) became mandatory for European marketing-authorization of adult treatments, unless...
39.
van Rheenen W, van der Spek R, Bakker M, van Vugt J, Hop P, Zwamborn R, et al.
Nat Genet
. 2022 Feb;
54(3):361.
PMID: 35102318
No abstract available.
40.
Osmanovic A, Gogol I, Martens H, Widjaja M, Muller K, Schreiber-Katz O, et al.
Genes (Basel)
. 2022 Jan;
13(1).
PMID: 35052424
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive upper and lower motor neuron (LMN) loss. As ALS and other neurodegenerative diseases share genetic risk factors, we...